hyperlipidemia
Conditions
Interventions
None listed
Sponsors
Kindai University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Individuals aged 18 years or older at the time of informed consent who were diagnosed with dyslipidemia Individuals who had been treated with pemafibrate for at least 24 weeks after treatment initiation Patients who had been receiving statin therapy for at least 12 weeks at the time of pemafibrate initiation and continued the statin without any change in type or dosage Individuals with LDL-C>100 mg/dL at the time of pemafibrate initiation Individuals with triglyceride (TG) levels <400 mg/dL at the time of pemafibrate initiation Individuals who received an explanation regarding study participation, fully understood the study, and provided written informed consent of their own free will
Exclusion criteria
Exclusion criteria: Patients who meet any of the contraindications for pemafibrate Patients who had addition of, or a change in the dosage of, lipid-lowering medications within 12 weeks prior to the initiation of pemafibrate Patients who had addition of, or a change in the dosage of, oral steroid preparations, thyroid hormone preparations, or antithyroid drugs within 12 weeks prior to the initiation of pemafibrate Patients who are otherwise judged by the investigator to be unsuitable for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change in LDL-C from baseline at 24 weeks after initiation of pemafibrate treatment. | — |
Countries
Japan
Contacts
Public ContactYoshihisa Hiromine
Kindai University Faculty of Medicine Department of Endocrinology, Metabolism and Diabetes
Outcome results
None listed